Stock comparison
Merck & Co., Inc. is 82.3x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($308.78 B vs $3.75 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRK is larger
Merck & Co., Inc. is 82.3x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($308.78 B vs $3.75 B).
Market value leader
MRK
Merck & Co., Inc. is 82.3x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($308.78 B vs $3.75 B).
Revenue leader
MRK
KNSA: $677.56M vs MRK: $65.01B.
Profit leader
MRK
KNSA: $59.01M vs MRK: $18.25B.
Margin leader
MRK
KNSA: 8.7% vs MRK: 28.1% net margin.
| Metric | KNSA | MRK |
|---|---|---|
| Market cap | $3.75 B | $308.78 B |
| US-listed rank | #1663 | #45 |
| Revenue (latest FY) | $677.56M | $65.01B |
| Net income (latest FY) | $59.01M | $18.25B |
| Net margin | 8.7% | 28.1% |
| P/E (trailing FY) | 63.6x | 16.9x |
| SEC filings | 733 | 998 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Merck & Co., Inc. is 82.3x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($308.78 B vs $3.75 B).
In their latest fiscal years, Kiniksa Pharmaceuticals, Ltd. reported $677.56M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Kiniksa Pharmaceuticals, Ltd. and Merck & Co., Inc., or browse the full rankings.